ES2032468T3 - Procedimiento para la preparacion de reactivos inmunologicos para la deteccion y eliminacion de celulas dianas especificas. - Google Patents

Procedimiento para la preparacion de reactivos inmunologicos para la deteccion y eliminacion de celulas dianas especificas.

Info

Publication number
ES2032468T3
ES2032468T3 ES198787430031T ES87430031T ES2032468T3 ES 2032468 T3 ES2032468 T3 ES 2032468T3 ES 198787430031 T ES198787430031 T ES 198787430031T ES 87430031 T ES87430031 T ES 87430031T ES 2032468 T3 ES2032468 T3 ES 2032468T3
Authority
ES
Spain
Prior art keywords
cells
reagents
radioactive
elimination
procedure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES198787430031T
Other languages
English (en)
Inventor
Jacques Barbet
Michel Delaage
Jean-Marc Le Doussal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunotech SAS
Original Assignee
Immunotech Partners SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunotech Partners SA filed Critical Immunotech Partners SA
Application granted granted Critical
Publication of ES2032468T3 publication Critical patent/ES2032468T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Optics & Photonics (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

SE PROPORCIONAN REACTIVOS INMUNOLOGICOS QUE CONSTAN DE A) CONJUGADOS DE ANTICUERPOS O FRAGMENTOS, QUE TIENEN UNA ESPECIFICIDAD ANTICELULAR Y UNA ESPECIFICIDAD ANTI-AFTENO, Y B) TRAZADORES SINTETICOS QUE CONTIENEN POR LO MENOS DOS PUNTOS DE AFTENO Y POR LO MENOS UN PUNTO ADECUADO PARA LIGAR ISOTOPOS RADIACTIVOS, IONES PARAMAGNETICOS, MEDICAMENTOS O TOXINAS. ESTOS REACTIVOS SE PUEDEN UNIR A CELULAS BLANCO DE UN MODO ESPECIFICO Y EL TRAZADOR LOCALIZA PREFERENCIALMENTE EN LA MEMBRANA DE CELULAS QUE LLEVAN ANTIGENO, AUN EN PRESENCIA DE EXCESO DE CONJUGADOS DE ANTICUERPO (MEJORA DE AFINIDAD). ESTOS REACTIVOS SE EMPLEAN DE MODO UTIL, IN VITRO O IN VIVO, PARA DETECTAR TUMORES, METASTASIS U OTRAS LESIONES DE TEJIDOS, CUANDO EL TRAZADOR SINTETICO LLEVA COMPUESTOS RADIACTIVOS O PARAMAGNETICOS, Y PARA DESTRUIR CELULAS BLANCO CUANDO EL TRAZADOR SINTETICO LLEVA COMPUESTOS RADIACTIVOS O MEDICAMENTOS O TOXINAS.
ES198787430031T 1986-09-19 1987-09-16 Procedimiento para la preparacion de reactivos inmunologicos para la deteccion y eliminacion de celulas dianas especificas. Expired - Lifetime ES2032468T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8613146A FR2604092B1 (fr) 1986-09-19 1986-09-19 Immunoreactifs destines a cibler les cellules animales pour leur visualisation ou leur destruction in vivo

Publications (1)

Publication Number Publication Date
ES2032468T3 true ES2032468T3 (es) 1993-02-16

Family

ID=9339117

Family Applications (1)

Application Number Title Priority Date Filing Date
ES198787430031T Expired - Lifetime ES2032468T3 (es) 1986-09-19 1987-09-16 Procedimiento para la preparacion de reactivos inmunologicos para la deteccion y eliminacion de celulas dianas especificas.

Country Status (11)

Country Link
US (1) US5256395A (es)
EP (1) EP0263046B1 (es)
JP (1) JP2612454B2 (es)
KR (1) KR900005622B1 (es)
AT (1) ATE74769T1 (es)
AU (1) AU613318B2 (es)
CA (1) CA1306414C (es)
DE (1) DE3778281D1 (es)
ES (1) ES2032468T3 (es)
FR (1) FR2604092B1 (es)
GR (1) GR3004914T3 (es)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6416738B1 (en) 1973-12-07 2002-07-09 Neorx Corporation Pretargeting methods and compounds
US6075010A (en) * 1992-06-09 2000-06-13 Neorx Corporation Small molecular weight ligand-hexose containing clearing agents
US5053226A (en) * 1987-07-15 1991-10-01 Board Of Regents, The University Of Texas System Monoclonal antibodies binding platinum complexes
AU609939B2 (en) * 1988-02-03 1991-05-09 University Of Melbourne, The Tumour imaging
CA1339775C (en) * 1988-06-10 1998-03-24 Shuzo Matsushita Antibody 0.5b to hiv-i gp 120 modified with toxic substance
US5439665A (en) * 1988-07-29 1995-08-08 Immunomedics Detection and treatment of infectious and inflammatory lesions
WO1990012109A1 (en) * 1989-03-30 1990-10-18 Board Of Regents, The University Of Texas System Monoclonal antibodies binding platinum complexes
FR2652004B1 (fr) * 1989-09-21 1994-10-28 Immunotech Partners Nouveaux derives hydrophiles, application au diagnostic et a la therapeutique, kits diagnostiques ou therapeutiques et reactifs immunologiques.
US5273743A (en) * 1990-03-09 1993-12-28 Hybritech Incorporated Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent
US5684137A (en) * 1990-09-28 1997-11-04 Neorx Corporation S3 N chelating compounds for the radiolabeling of ligands, anti-ligands or other proteins
US6685930B1 (en) * 1991-03-27 2004-02-03 Tanox, Inc. Methods and substances for recruiting therapeutic agents to solid tumors
US5364612A (en) * 1991-05-06 1994-11-15 Immunomedics, Inc. Detection of cardiovascular lesions
US6096289A (en) 1992-05-06 2000-08-01 Immunomedics, Inc. Intraoperative, intravascular, and endoscopic tumor and lesion detection, biopsy and therapy
CA2134239C (en) * 1992-06-09 2004-11-23 Donald B. Axworthy Pretargeting methods and compounds
US5976535A (en) * 1992-06-09 1999-11-02 Neorx Corporation Pretargeting protocols for the enhanced localization of cytotoxins to target sites and cytotoxic combinations useful therefore
US5578287A (en) * 1992-06-09 1996-11-26 Neorx Corporation Three-step pretargeting methods using improved biotin-active agent
US5541287A (en) * 1992-06-09 1996-07-30 Neorx Corporation Pretargeting methods and compounds
US6217869B1 (en) 1992-06-09 2001-04-17 Neorx Corporation Pretargeting methods and compounds
US5911969A (en) 1992-06-09 1999-06-15 Neorx Corporation Pretargeting protocols for enhanced localization of active agents to target sites
US6358490B2 (en) 1992-06-09 2002-03-19 Neorx Corporation Three-step pretargeting methods and compounds
US6022966A (en) * 1993-11-22 2000-02-08 Neorx Corporation Pretargeting methods and compounds
US5624896A (en) * 1992-06-09 1997-04-29 Neorx Corporation Clearing agents useful in pretargeting methods
US6228362B1 (en) 1992-08-21 2001-05-08 Immunomedics, Inc. Boron neutron capture therapy using pre-targeting methods
GB9300686D0 (en) * 1993-01-15 1993-03-03 Imp Cancer Res Tech Compounds for targeting
GB2300859B (en) * 1993-01-15 1997-06-18 Imp Cancer Res Tech Compounds comprising a target cell-specific portion and a further portion
WO1995015319A1 (en) * 1993-12-03 1995-06-08 Bracco S.P.A. Paramagnetic chelates for nuclear magnetic resonance diagnosis
US5561043A (en) * 1994-01-31 1996-10-01 Trustees Of Boston University Self-assembling multimeric nucleic acid constructs
US6908903B1 (en) 1994-12-07 2005-06-21 Aletheon Pharmaceuticals, Inc. Cluster clearing agents
US6172045B1 (en) 1994-12-07 2001-01-09 Neorx Corporation Cluster clearing agents
DE19500665A1 (de) * 1995-01-12 1996-07-18 Axel Prof Dr Haase Verfahren zur ortsauflösenden Abbildung eines Bereiches eines biologischen Objektes mit Hilfe elektromagnetischer Strahlen unter Applikation von Kontrastmittel
US5955605A (en) * 1995-02-21 1999-09-21 Neorx Corporation Biotinidase resistant biotin-DOTA conjugates
US6770261B2 (en) * 1995-06-02 2004-08-03 Research Corporation Technologies Magnetic resonance imaging agents for the detection of physiological agents
US6713045B1 (en) 1995-06-02 2004-03-30 Research Corporation Technologies, Inc. Targeted magnetic resonance imaging agents for the detection of physiological processes
US7011812B1 (en) * 1996-05-03 2006-03-14 Immunomedics, Inc. Targeted combination immunotherapy of cancer and infectious diseases
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
US5900228A (en) 1996-07-31 1999-05-04 California Institute Of Technology Bifunctional detection agents having a polymer covalently linked to an MRI agent and an optical dye
US6713046B1 (en) * 1997-10-27 2004-03-30 Research Corporation Technologies Magnetic resonance imaging agents for the delivery of therapeutic agents
AU752812B2 (en) 1997-11-17 2002-10-03 Research Corporation Technologies, Inc. Magnetic resonance imaging agents for the detection of physiological agents
US7833528B2 (en) * 1998-06-22 2010-11-16 Immunomedics, Inc. Use of multispecific, non-covalent complexes for targeted delivery of therapeutics
US7052872B1 (en) 1999-06-22 2006-05-30 Immunomedics, Inc. Bi-specific antibodies for pre-targeting diagnosis and therapy
US7405320B2 (en) 1998-06-22 2008-07-29 Immunomedics, Inc. Therapeutic and diagnostic conjugates for use with multispecific antibodies
US6962702B2 (en) 1998-06-22 2005-11-08 Immunomedics Inc. Production and use of novel peptide-based agents for use with bi-specific antibodies
US7074405B1 (en) 1998-06-22 2006-07-11 Immunomedics, Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
US7387772B1 (en) 1999-06-22 2008-06-17 Immunimedics, Inc. Chimeric, human and humanized anti-CSAP monoclonal antibodies
US7138103B2 (en) 1998-06-22 2006-11-21 Immunomedics, Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
US6361774B1 (en) * 1999-09-17 2002-03-26 Immunomedics, Inc. Methods and compositions for increasing the target-specific toxicity of a chemotherapy drug
US6576155B1 (en) * 1998-11-10 2003-06-10 Biocrystal, Ltd. Fluorescent ink compositions comprising functionalized fluorescent nanocrystals
US6673333B1 (en) 2000-05-04 2004-01-06 Research Corporation Technologies, Inc. Functional MRI agents for cancer imaging
WO2001097855A2 (en) * 2000-06-20 2001-12-27 Immunomedics, Inc. Targeted combination immunotherapy of cancer and infectious diseases
WO2002006287A2 (en) 2000-07-17 2002-01-24 California Institute Of Technology Macrocyclic mri contrast agents
WO2002028441A2 (en) 2000-10-04 2002-04-11 California Institute Of Technology Magnetic resonance imaging agents for in vivo labeling and detection of amyloid deposits
US20030004236A1 (en) * 2001-04-20 2003-01-02 Meade Thomas J. Magnetic resonance imaging agents for detection and delivery of therapeutic agents and detection of physiological substances
US20030135108A1 (en) * 2001-05-02 2003-07-17 Silva Robin M. High throughput screening methods using magnetic resonance imaging agents
US20020197648A1 (en) * 2001-05-02 2002-12-26 Silva Robin M. High throughput screening methods using magnetic resonance imaging agents
EP1418808B1 (en) * 2001-07-30 2005-11-30 SmithKline Beecham Corporation Imaging marker transgenes
IL161417A0 (en) 2001-10-15 2004-09-27 Immunomedics Inc Affinity enhancement agents
WO2003048207A2 (en) * 2001-11-28 2003-06-12 Immunomedics, Inc. Anti-dota antibody
US7011816B2 (en) 2001-12-26 2006-03-14 Immunomedics, Inc. Labeling targeting agents with gallium-68 and gallium-67
PL372144A1 (en) * 2001-12-26 2005-07-11 Immunomedics, Inc. Methods of generating multispecific, multivalent agents from v sb h /sb and v sb l /sb domains
CA2478047C (en) 2002-03-01 2014-01-21 Immunomedics, Inc. Rs7 antibodies
US20040018557A1 (en) * 2002-03-01 2004-01-29 Immunomedics, Inc. Bispecific antibody point mutations for enhancing rate of clearance
US20030198597A1 (en) * 2002-04-22 2003-10-23 Meade Thomas J. Novel macrocyclic activatible magnetic resonance imaging contrast agents
CA2487692A1 (en) * 2002-05-29 2003-12-11 Immunomedics, Inc. Methods and compositions for radioimmunotherapy of brain and cns tumors
US6911083B2 (en) * 2002-06-11 2005-06-28 Tokyo Institute Of Technology Method for producing powders made of gallium nitride and apparatus for producing the same
US7597876B2 (en) * 2007-01-11 2009-10-06 Immunomedics, Inc. Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules
US7993626B2 (en) 2007-01-11 2011-08-09 Immunomedics, Inc. Methods and compositions for F-18 labeling of proteins, peptides and other molecules
ES2524767T3 (es) 2002-06-14 2014-12-12 Immunomedics, Inc. Anticuerpo monoclonal humanizado HPAM4
US7563433B2 (en) * 2007-01-11 2009-07-21 Immunomedics, Inc. Methods and compositions for F-18 labeling of proteins, peptides and other molecules
US9701754B1 (en) 2002-10-23 2017-07-11 City Of Hope Covalent disulfide-linked diabodies and uses thereof
AU2003283599C1 (en) * 2002-11-15 2009-06-25 Immunomedics, Inc. Use of multi-specific, non-covalent complexes for targeted delivery of therapeutics
JP3931818B2 (ja) * 2003-02-13 2007-06-20 株式会社デンソー 車両用空調装置
US20050003403A1 (en) * 2003-04-22 2005-01-06 Rossi Edmund A. Polyvalent protein complex
JP4937751B2 (ja) * 2003-06-13 2012-05-23 イミューノメディクス、インコーポレイテッド Ｄ−アミノ酸ペプチド
CA2531118C (en) * 2003-07-01 2013-01-08 Immunomedics, Inc. Multivalent carriers of bi-specific antibodies
CA2534898A1 (en) * 2003-08-08 2005-02-17 Immunomedics, Inc. Bispecific antibodies for inducing apoptosis of tumor and diseased cells
US20050059101A1 (en) * 2003-09-10 2005-03-17 Gordon Ringold Bivalent targeting of cell surfaces
EP1602928A1 (en) * 2004-06-01 2005-12-07 Universiteit Maastricht Process and kit for determining binding parameters of bioaffinity binding reactions
ES2381557T3 (es) 2004-08-03 2012-05-29 Innate Pharma Métodos terapéuticos y de diagnóstico y composiciones para determinar 4IG-B7-H3 y su receptor homólogo en las células NK
RU2481356C2 (ru) 2004-12-28 2013-05-10 Иннейт Фарма Моноклональные антитела против nkg2a
CN101171034B (zh) 2005-03-03 2014-06-18 免疫医疗公司 人源化l243抗体
EP1934260B1 (en) 2005-10-14 2017-05-17 Innate Pharma Compositions and methods for treating proliferative disorders
EP2674440B1 (en) 2005-12-16 2019-07-03 IBC Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
ATE509033T1 (de) 2006-03-20 2011-05-15 Univ California Manipulierte anti-prostatastammzellenantigen (psca)-antikörper für krebs-targeting
US8545809B2 (en) 2007-01-11 2013-10-01 Immunomedics, Inc. Methods and compositions for improved 18F labeling of proteins, peptides and other molecules
US8889100B2 (en) 2007-01-11 2014-11-18 Immunomedics, Inc. Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules
US8398956B2 (en) 2007-01-11 2013-03-19 Immunomedics, Inc. In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
US8153100B2 (en) * 2007-01-11 2012-04-10 Immunomedics, Inc. Methods and compositions for F-18 labeling of proteins, peptides and other molecules
US8709382B2 (en) 2007-01-11 2014-04-29 Immunomedics, Inc. Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules
US8940298B2 (en) 2007-09-04 2015-01-27 The Regents Of The University Of California High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection
JP5906090B2 (ja) 2009-02-17 2016-04-20 コーネル・リサーチ・ファンデーション・インコーポレイテッドＣｏｒｎｅｌｌ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ， Ｉｎｃｏｒｐｏｒａｔｅｄ 癌の診断のための方法およびキットならびに治療価の推定
WO2011034660A1 (en) 2009-09-16 2011-03-24 Immunomedics, Inc. Class i anti-cea antibodies and uses thereof
CA3040276A1 (en) 2009-12-02 2011-06-09 Imaginab, Inc. J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use
IN2012DN03354A (es) 2009-12-02 2015-10-23 Immunomedics Inc
IN2012DN03177A (es) 2009-12-04 2015-09-25 Immunomedics Inc
AU2012250924B2 (en) 2011-05-02 2017-05-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
CA2935748A1 (en) 2014-02-25 2015-09-03 Immunomedics, Inc. Humanized rfb4 anti-cd22 antibody
PL3204018T3 (pl) 2014-10-07 2022-01-03 Immunomedics, Inc. Neoadiuwantowe zastosowanie koniugatów przeciwciało-lek
CA2968853A1 (en) * 2014-11-26 2016-06-02 Baofa Yu Hapten-enhanced chemoimmunotherapy by ultra-minimum incision personalized intratumoral chemoimmunotherapy
EP3286224A4 (en) 2015-04-22 2018-11-14 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
JP6872181B2 (ja) 2015-05-20 2021-05-19 国立大学法人 鹿児島大学 ＩｇＧ結合ペプチドによる抗体の特異的修飾
PL3316885T3 (pl) 2015-07-01 2021-12-06 Immunomedics, Inc. Immunokoniugaty przeciwciało-sn-38 z linkerem cl2a
CN108136012B (zh) 2015-08-07 2022-10-04 伊麦吉纳博公司 靶向分子的抗原结合构建体
US10634680B2 (en) 2016-04-26 2020-04-28 University Of Utah Research Foundation Target-binding activated split reporter systems for analyte detection and related components and methods
DK3470418T3 (da) * 2016-06-13 2024-09-30 Univ Kagoshima Site-specifik radioisotop-mærket antistof ved brug af using iggbindende peptid
WO2018147960A1 (en) 2017-02-08 2018-08-16 Imaginab, Inc. Extension sequences for diabodies

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3927193A (en) * 1973-05-18 1975-12-16 Hoffmann La Roche Localization of tumors by radiolabelled antibodies
US4401764A (en) * 1980-02-07 1983-08-30 Technicon Instruments Corporation Immunoassays employing labeled reagent and a conjugate having two binding sites
US4331647A (en) * 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
WO1981002522A1 (en) * 1980-03-03 1981-09-17 M Goldenberg Tumor localization and therapy with labeled antibodies and antibody fragments specific to tumor-associated markers
JPS579724A (en) * 1980-05-21 1982-01-19 Teijin Ltd Reactive polymer containing bonded cytotoxic substance and its preparation
US4714681A (en) * 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4433059A (en) * 1981-09-08 1984-02-21 Ortho Diagnostic Systems Inc. Double antibody conjugate
AT392004B (de) * 1981-10-27 1991-01-10 Hybritech Inc Verfahren zur herstellung eines monoklonalen antikoerpers gegen tumor-assoziiertes antigen und dessen verwendung
US4445421A (en) * 1981-11-06 1984-05-01 The Charles Stark Draper Laboratory, Inc. Helicopter swashplate controller
US4444878A (en) * 1981-12-21 1984-04-24 Boston Biomedical Research Institute, Inc. Bispecific antibody determinants
CA1213229A (en) * 1982-04-12 1986-10-28 Gary S. David Antibodies having dual specificities, their preparation and uses therefor
US4470925A (en) * 1982-05-05 1984-09-11 E. I. Du Pont De Nemours And Company Immunoglobulin half-molecules and process for producing hybrid antibodies
US4446233A (en) * 1982-05-05 1984-05-01 E. I. Du Pont De Nemours And Company Homogeneous immunoassay using covalent hybrid antibodies
US4454106A (en) * 1982-06-07 1984-06-12 Gansow Otto A Use of metal chelate conjugated monoclonal antibodies
US4472509A (en) * 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4741900A (en) * 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US4490473A (en) * 1983-03-28 1984-12-25 Panab Labeled antibodies and methods
US4664911A (en) * 1983-06-21 1987-05-12 Board Of Regents, University Of Texas System Immunotoxin conjugates employing toxin B chain moieties
GB2148299B (en) * 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
US4661444A (en) * 1984-03-29 1987-04-28 Ortho Diagnostic Systems Inc. Homogeneous immunoassays employing double antibody conjugates comprising anti-idiotype antibody
WO1985004811A1 (en) * 1984-04-23 1985-11-07 Boston Biomedical Research Institute, Inc. Bispecific antibody determinants
US4722892A (en) * 1984-08-31 1988-02-02 Meares Claude F Monoclonal antibodies against metal chelates
GB8422452D0 (en) * 1984-09-05 1984-10-10 Serono Diagnostics Ltd Assay
US4760142A (en) * 1984-11-27 1988-07-26 Hoechst Celanese Corporation Divalent hapten derivatives
CA1282069C (en) * 1985-09-12 1991-03-26 Damon L. Meyer Antibody complexes of hapten-modified diagnostic or therapeutic agents
US4676980A (en) * 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4863713A (en) * 1986-06-23 1989-09-05 The Board Of Trustees Of Leland Stanford Jr. Univ. Method and system for administering therapeutic and diagnostic agents

Also Published As

Publication number Publication date
JPS63159327A (ja) 1988-07-02
CA1306414C (en) 1992-08-18
EP0263046A1 (en) 1988-04-06
DE3778281D1 (de) 1992-05-21
AU613318B2 (en) 1991-08-01
ATE74769T1 (de) 1992-05-15
EP0263046B1 (en) 1992-04-15
US5256395A (en) 1993-10-26
FR2604092B1 (fr) 1990-04-13
GR3004914T3 (es) 1993-04-28
JP2612454B2 (ja) 1997-05-21
KR900005622B1 (ko) 1990-07-31
AU7865687A (en) 1988-04-21
KR880004312A (ko) 1988-06-07
FR2604092A1 (fr) 1988-03-25

Similar Documents

Publication Publication Date Title
GR3004914T3 (es)
BR0208603A (pt) Marcadores de tumor para carcinoma de células renais
PT1157041E (pt) Anticorpos para terapia e diagnostico de cancro
BR9914116A (pt) Composições e métodos para imunoterapia especìfica de wt1
BR0009537A (pt) Composições para tratamento e diagnóstico de câncer de mama e métodos para seu uso
ES2093778T3 (es) Nuevos anticuerpos y metodos para su uso.
SE8804068D0 (sv) Reliable document authentication system
NO20001238L (no) Monoklonalt antistoff som induserer apoptose
ES8706965A1 (es) Un metodo de formacion de un conjugado de proteina y quelato metalico
GB8915512D0 (en) Silver enhanced gold-labelled immuno assay method
ES2138102T3 (es) Procedimiento para la deteccion de antigeno urinario asociado a tumores.
OA08485A (fr) Monoclonal antibodies and antigen for human non-small cell lung carcinoma and certain other human carcinomas.
FI830573A7 (fi) Syövän diagnoosissa ja hoidossa hyödylliset vasta-aineet ja antigeenit.
DE69824023D1 (de) Peptide, die agonisten oder antagonisten des karzinoembrionalen antigens (cea) sind
EP0232179A3 (en) Assay for human breast cancer
ES2101695T3 (es) Haptoglobina relacionada con el cancer (hpr).
BR9903250A (pt) Antìgenos e imunoanálises para diagnóstico da doença de chagas.
ES2053712T3 (es) Un antigeno proteico reactivo y fragmentos del mismo.
Touitou et al. Tumour marker antigens during menses and pregnancy
DK0495910T3 (da) Fremstilling og anvendelse af humant nm23-H2-protein og derimod rettede antistoffer
SG3291G (en) Reagent for use in detecting antibody to human t-cell leukaemia virus antigen
ES2176523T3 (es) Procedimiento para la deteccion de la enfermedad de alzheimer.
DE3670632D1 (de) Histamin-derivate, immunogen-konjugate und dadurch induzierte antikoerper.
ES2136085T3 (es) Fragmentos de hgpiib y su uso en procedimientos que permiten la determinacion in vitro de eventos tromboticos in vivo.
HUANG et al. THE USE OF THE INDIRECT ELISA IN THE DETERMINATION OF ANTIENDOME-TRIAL ANTIBODIES AND ITS CLINICAL APPLICATION

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 263046

Country of ref document: ES